Indication
Progressive chronic lymphocytic leukemia
Progressive chronic lymphocytic leukemia represents an active, advancing clinical phase of a hematologic malignancy characterized by the clonal proliferation and accumulation of mature-appearing, immunologically dysfunctional B lymphocytes primarily affecting the peripheral blood, bone marrow, spleen, and lymph nodes. Read more about Progressive chronic lymphocytic leukemia
60 drugs 53 manufacturers
Drugs that treat it
Common Progressive chronic lymphocytic leukemia therapies.
RITUXAN (rituximab)
FLUDARABINE PHOSPHATE
ARZERRA (ofatumumab)
FLUDARABINE (fludarabine phosphate)
FLUDARABINE PHOSPHATE
FLUDARABINE PHOSPHATE
FLUDARABINE (fludarabine phosphate)
FLUDARABINE (fludarabine phosphate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonProgressive chronic lymphocytic leukemia represents an active, advancing clinical phase of a hematologic malignancy characterized by the clonal proliferation and accumulation of mature-appearing, immunologically dysfunctional B lymphocytes primarily affecting the peripheral blood, bone marrow, spleen, and lymph nodes.
Unlike stable or indolent disease, this progressive state is defined by worsening tumor burden and clinical deterioration that warrants therapeutic intervention.
Hallmarks include progressive marrow failure presenting as worsening anemia or thrombocytopenia, rapidly doubling lymphocytosis, massive or symptomatic lymphadenopathy and splenomegaly, or debilitating constitutional B symptoms such as unintentional weight loss, severe fatigue, fevers, and night sweats.
- nih.gov
Progressive chronic lymphocytic leukemia represents an active, advancing clinical phase of a hematologic malignancy characterized by the clonal proliferation and accumulation of mature-appearing, immunologically dysfunctional B lymphocytes primarily affecting the peripheral blood, bone marrow, spleen, and lymph nodes Unlike stable or indolent disease, this progressive state is defined by worsening tumor burden and clinical deterioration that warrants therapeutic intervention
- nih.gov
Progressive chronic lymphocytic leukemia represents an active, advancing clinical phase of a hematologic malignancy characterized by the clonal proliferation and accumulation of mature-appearing, immunologically dysfunctional B lymphocytes primarily affecting the peripheral blood, bone marrow, spleen, and lymph nodes
- peerview.com
Unlike stable or indolent disease, this progressive state is defined by worsening tumor burden and clinical deterioration that warrants therapeutic intervention Hallmarks include progressive marrow failure presenting as worsening anemia or thrombocytopenia, rapidly doubling lymphocytosis, massive or symptomatic lymphadenopathy and splenomegaly, or debilitating constitutional B symptoms such as unintentional weight loss, severe fatigue, fevers, and night sweats
- doctorabad.com
Hallmarks include progressive marrow failure presenting as worsening anemia or thrombocytopenia, rapidly doubling lymphocytosis, massive or symptomatic lymphadenopathy and splenomegaly, or debilitating constitutional B symptoms such as unintentional weight loss, severe fatigue, fevers, and night sweats
Personalize your experience
Follow Progressive chronic lymphocytic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.